Avanos Medical (NYSE:AVNS) Issues Earnings Results, Beats Estimates By $0.10 EPS

Avanos Medical (NYSE:AVNS) issued its quarterly earnings data on Wednesday. The company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.10, Zacks reports. Avanos Medical had a negative net margin of 66.89% and a positive return on equity of 6.16%. The company had revenue of $177.80 million for the quarter, compared to the consensus estimate of $164.50 million. During the same quarter in the prior year, the firm earned $0.33 earnings per share. The firm’s revenue for the quarter was up 4.3% compared to the same quarter last year. Avanos Medical updated its FY 2025 guidance to 0.850-0.950 EPS.

Avanos Medical Price Performance

NYSE AVNS opened at $10.65 on Thursday. The business’s fifty day moving average is $11.71 and its 200 day moving average is $11.92. Avanos Medical has a fifty-two week low of $9.30 and a fifty-two week high of $21.12. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.58 and a current ratio of 2.64. The company has a market capitalization of $494.16 million, a PE ratio of -1.06 and a beta of 1.19.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on AVNS shares. Zacks Research raised Avanos Medical to a “hold” rating in a report on Tuesday, August 12th. Wall Street Zen cut Avanos Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Avanos Medical in a research report on Tuesday, October 14th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Avanos Medical presently has an average rating of “Reduce”.

Insider Activity at Avanos Medical

In related news, Director Gary Blackford acquired 40,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 13th. The stock was bought at an average cost of $10.99 per share, for a total transaction of $439,600.00. Following the purchase, the director owned 40,000 shares in the company, valued at $439,600. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 2.64% of the stock is owned by company insiders.

Hedge Funds Weigh In On Avanos Medical

Several large investors have recently added to or reduced their stakes in AVNS. Russell Investments Group Ltd. boosted its position in shares of Avanos Medical by 969.3% in the second quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock worth $31,000 after purchasing an additional 2,307 shares during the period. Tower Research Capital LLC TRC boosted its holdings in Avanos Medical by 433.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock worth $77,000 after buying an additional 5,083 shares during the period. State of Wyoming boosted its holdings in Avanos Medical by 64.4% in the 2nd quarter. State of Wyoming now owns 17,273 shares of the company’s stock worth $211,000 after buying an additional 6,765 shares during the period. Cerity Partners LLC purchased a new stake in Avanos Medical in the 2nd quarter worth $272,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Avanos Medical by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock valued at $386,000 after acquiring an additional 1,121 shares during the period. Hedge funds and other institutional investors own 95.17% of the company’s stock.

About Avanos Medical

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.